Organized by the Society for Laboratory Automation and Screening (SLAS), the premier automation conference in Europe, the SLAS Europe 2025 (20-22. May 2025), will showcase the latest technologies and drug discovery enablers. As part of its preview series, European Biotechnology Magazine profiles 12 of Europe’s most innovative AveNew SMEs – this edition features Austrian LifeTaq-Analytics GmbH.
Unlocking the treasure trove
BackgroundThe Hamburg-based company Indivumed has repositioned itself, sending a clear message with a recent change in leadership: A new chapter is beginning with the focus on discovering and developing novel therapeutic targets for innovative cancer therapies. |transkript spoke with Prof. Dr. Hartmut Juhl and Dr. Matthias Evers.
C4X Discovery bags milestone for IL-17A blocker from Sanofi
Latest NewsC4X Discovery Holdings Ltd has received a €8m milestone payment from the French pharmaceutical company Sanofi for its preclinical IL-17A inhibitor. This payment is based on a licence agreement from 2021, under which the British company could receive up to €414m, including royalties.
New way to target mitochondrial diseases
Latest NewsPharmacologists at the University of Göttingen, Germany, have reported a simple way to target and silence individual mitochondrial mRNAs in vivo.
Biopharma transformation: leading drug discovery start-ups of 2025
Associations, Latest NewsBritish company Wildcat Laboratory Solutions Ltd and Hamburg-based mo:re GmbH have received the New Product Award from the Society for Laboratory Automation and Screening (SLAS) in recognition of new technologies with potential to drive industry transformation. The award for the most promising start-up was conferred upon Swiss firm Oryl Photonics SA.
Countdown to SLAS Europe: ThirdLaw Molecular Inc.
Associations, Latest NewsOrganised by the Society for Laboratory Automation and Screening (SLAS), SLAS Europe currently is taking place in Hamburg from 20–22 May. As part of a special series, European Biotechnology Magazine is profiling twelve of the most innovative exhibiting SMEs supported under the SLAS AveNew programme. Among them is US-based ThirdLaw Molecular Inc.
BioNTech Secures £129m UK Backing
Latest NewsBioNTech is set to open a research centre for cancer therapy in the United Kingdom, much to the delight of the British government, which is helping pave the way with a substantial financial boost.
Countdown to SLAS Europe: LifeTaq Analytics GmbH
Associations, Latest NewsOrganized by the Society for Laboratory Automation and Screening (SLAS), the premier automation conference in Europe, the SLAS Europe 2025 (20-22. May 2025), will showcase the latest technologies and drug discovery enablers. As part of its preview series, European Biotechnology Magazine profiles 12 of Europe’s most innovative AveNew SMEs – this edition features Austrian LifeTaq-Analytics GmbH.
SV Health Raises US$269m for Dementia Start-ups
Latest NewsBritish investment firm SV Health Investors has secured US$269m for its second fund, Dementia Discovery Fund, or DDF-2. The capital will be used to invest in companies developing or enabling novel therapeutics for dementia.
Massalia Therapeutics kicks off with seed financing
Latest NewsFrench biotech firm Massalia Therapeutics SA has been launched, backed by seed funding from Landmark Bioventures, the company founders and their network. The company claims to have an IND-ready, first-in-class drug candidate poised to target both cancer and fibrosis.
Ingestible biosensor marks future of medicine
Latest NewsBelgian Imec researchers have presented a prototype of an ingestible sensor for long-term gut health monitoring that is able to measure acidifidation that is linked to gut inflammation.